Ivabradin Axiromed

Ivabradine, the active ingredient in Ivabradin Axiomed, is a If channel inhibitor presented as an oral formulation for oral use. It is used to manage chronic stable angina and certain forms of heart failure in adult patients.

GNH USA supplies Ivabradin Axiomed as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradin Axiomed acts on the cardiac If current to reduce heart rate in conditions where heart‑rate control improves outcomes. - Chronic stable angina: lowers heart rate to decrease frequency of angina attacks. - Heart failure with reduced ejection fraction: improves symptoms and may reduce hospitalisations. - Patients intolerant to beta‑blockers: provides an alternative method of heart‑rate reduction.

Adverse reactions have been reported with ivabradine use.

Common Side Effects: - Bradycardia: slowed resting heart rate. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache. - Dizziness.

Serious or Rare Side Effects: - Symptomatic severe bradycardia or syncope. - Atrioventricular block. - Worsening of heart failure or decompensation.

Ivabradin Axiomed requires careful patient assessment and monitoring. - Cardiac monitoring: obtain baseline ECG and heart‑rate measurement before initiation. - Avoid in patients with resting heart rate below 60 bpm. - Caution in severe hepatic impairment: dose may need adjustment. - Concomitant use with strong CYP3A4 inhibitors: increased exposure may occur. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Store at ambient temperature (below 25°C): keep in the original pack, protect from moisture.

Ivabradin Axiomed can interact with several drug classes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise ivabradine plasma levels. - Other bradycardic agents (beta‑blockers, digoxin, diltiazem, verapamil): risk of excessive heart‑rate reduction. - Pacemaker‑dependent patients: potential interference with device function.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Antihypertensives that cause hypotension: monitor blood pressure for additive effects.